☆ 4.4 Article

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies

NEUROLOGY AND THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results

Ralf Gold et al.

Summary: This study assessed the long-term safety and efficacy of dimethyl fumarate (DMF) in multiple sclerosis patients for up to 13 years. The results demonstrate sustained safety and efficacy of DMF treatment, with low annualized relapse rates and a majority of patients showing no disability worsening over the long-term treatment period. This supports the positive benefit-risk profile of DMF for long-term RRMS treatment.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis The CONNECT Randomized Clinical Trial

Patrick Vermersch et al.

Summary: This study compares the efficacy, safety, and tolerability of dimethyl fumarate (DMF) and intramuscular interferon beta-1a (IFN beta-1a) in pediatric-onset multiple sclerosis (POMS). The study found that DMF-treated patients had a lower proportion of new or newly enlarging T2 lesions and a lower adjusted annualized relapse rate (ARR) compared to IFN beta-1a-treated patients. DMF was well tolerated.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Clinical Neurology

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

Erin E. Longbrake et al.

Summary: The study demonstrates that lymphocyte decreases were maintained over the 96-week DMF treatment, while immunoglobulins remained stable. CD4 (+) and CD8 (+) T cells correlated highly with ALC, and adverse event rates were similar across ALC subgroups.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article

Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate

Amber Salter et al.

International Journal of MS Care (2021)

Add to Collection

Article Clinical Neurology

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

Frank Dahlke et al.

Summary: The NO.MS data set contains information on over 35,000 patients and shows that disease activity and worsening differ across ages and phenotypes. Young patients benefit most from treatment, with disease activity highest in pediatric patients.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients

Tjalf Ziemssen et al.

Summary: The study found that young patients had lower disability scores compared to older patients at baseline but higher relapse rates, which significantly decreased in all age groups after 5 years of treatment. The proportion of patients with no clinical disease activity in year 4 varied among different age groups.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND

Pavle Repovic et al.

Summary: This study found that dimethyl fumarate may be an effective treatment option for relapsing multiple sclerosis patients who experience suboptimal response to glatiramer acetate. In both first switch and early MS switch patients, most patients showed significant improvement in relapse rates and symptoms after 12 months of DMF treatment.

NEUROLOGY AND THERAPY (2021)

Add to Collection

Article Clinical Neurology

Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study

Tine Iskov Kopp et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Long-term disability progression of pediatric-onset multiple sclerosis

Kyla A. Mckay et al.

NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC

T. Berger et al.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2019)

Add to Collection

Article Clinical Neurology

Changes in disability in people with multiple sclerosis: a 10-year prospective study

David Conradsson et al.

JOURNAL OF NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Early versus later treatment start in multiple sclerosis: a register-based cohort study

T. A. Chalmer et al.

EUROPEAN JOURNAL OF NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Xavier Montalban et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Xavier Montalban et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)

Stanley L. Cohan et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study

Kiren Kresa-Reahl et al.

CLINICAL THERAPEUTICS (2018)

Add to Collection

Review Clinical Neurology

Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS

Elizabeth A. Mills et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Medicine, General & Internal

Multiple sclerosis

Massimo Filippi et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

Add to Collection

Article Clinical Neurology

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

Ralf Gold et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Clinical Neurology

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

Ralf Gold et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Immunology

Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients

Qi Wu et al.

JOURNAL OF IMMUNOLOGY (2017)

Add to Collection

Article Clinical Neurology

New insights into the burden and costs of multiple sclerosis in Europe

Gisela Kobelt et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Clinical Neurology

New insights into the burden and costs of multiple sclerosis in Europe

Gisela Kobelt et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Clinical Neurology

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Ann Marie Weideman et al.

FRONTIERS IN NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

The relationship of age with the clinical phenotype in multiple sclerosis

A. Scalfari et al.

MULTIPLE SCLEROSIS JOURNAL (2016)

Add to Collection

Article Clinical Neurology

The relationship of age with the clinical phenotype in multiple sclerosis

A. Scalfari et al.

MULTIPLE SCLEROSIS JOURNAL (2016)

Add to Collection

Article Medicine, General & Internal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Robert J. Fox et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Clinical Neurology

Difference in Disease Burden and Activity in Pediatric Patients on Brain Magnetic Resonance Imaging at Time of Multiple Sclerosis Onset vs Adults

Emmanuelle Waubant et al.

ARCHIVES OF NEUROLOGY (2009)

Add to Collection

Article Clinical Neurology

Relapses in multiple sclerosis are age- and time-dependent

H. Tremlett et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)

Add to Collection

Article Clinical Neurology

Is late-onset multiple sclerosis associated with a worse outcome?

Helen Tremlett et al.

NEUROLOGY (2006)

Add to Collection

Article Clinical Neurology

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

CC Ford et al.

MULTIPLE SCLEROSIS JOURNAL (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.